Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.74 |
| ▸ | ESRRG | P62508 | 7/20 | 0.74 |
| ▸ | PSMB1 | P20618 | 7/20 | 0.73 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.73 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.65 |
| ▸ | ESRRB | O95718 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5075011 | 1.00 | ESR1 (0.74) | ESR1ESRRGPSMB1PSMB5PSMB2 | |
| SCHEMBL5075819 | 1.00 | ESR1 (0.74) | ESR1ESRRGPSMB1PSMB5PSMB2 | |
| SCHEMBL24354598 | 0.96 | ESR1 (0.82) | ESR1ESRRGPSMB1PSMB5PSMB2 | |
| SCHEMBL14539097 | 0.96 | ESR1 (0.82) | ESR1ESRRGPSMB1PSMB5PSMB2 | |
| SCHEMBL5075009 | 0.94 | PSMB1 (0.82) | ESR1ESRRGPSMB1PSMB5PSMB2 | |
| SCHEMBL5085438 | 0.94 | PSMB1 (0.82) | ESR1ESRRGPSMB1PSMB5PSMB2 | |
| SCHEMBL5075219 | 0.94 | PSMB1 (0.82) | ESR1ESRRGPSMB1PSMB5PSMB2 | |
| SCHEMBL5136332 | 0.91 | PSMB1 (0.89) | ESR1ESRRGPSMB1PSMB5PSMB2 | |
| SCHEMBL23266922 | 0.89 | ESR1 (0.81) | ESR1ESRRGPSMB1PSMB5PSMB2 | |
| SCHEMBL4637944 | 0.88 | ESR1 (0.74) | ESR1ESRRGPSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255089-A1 | Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | claimed |
| EP-1951250-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007062151-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | claimed |
| US-20080255089-A1 | Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
| US-20080255089-A1 | Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
| US-20080255089-A1 | Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
| EP-1951250-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062151-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062151-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255089-A1 | Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives | SHBG, ESR1, GPER1 | ESR1 2/4885ESRRG 7/4885PSMB1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.